

UCSF

UC San Francisco Previously Published Works

Title

Cognitive decline related to substance consumption in a Colombian kindred with familial Alzheimer's disease: A retrospective cohort study

Permalink

<https://escholarship.org/uc/item/1gp9b85d>

Journal

Alzheimer's & Dementia, 17(S10)

ISSN

1552-5260

Authors

Ramos-Perez, Claudia Patricia
Villalba, Arvey Camilo
Garcia, Jenny
et al.

Publication Date

2021-12-01

DOI

10.1002/alz.052860

Copyright Information

This work is made available under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives License, available at <https://creativecommons.org/licenses/by-nc-nd/4.0/>

Peer reviewed

Cognitive decline related to substance consumption in a Colombian kindred with familial Alzheimer's disease: A retrospective cohort study

Claudia Patricia Ramos-Perez^{1,2} | Arvey Camilo Villalba³ | Jenny Garcia⁴ | Sergio Lanata^{1,5} | Hugo Elias Lopez² | Daniel C Aguirre-Acevedo⁶ | Francisco Lopera⁷

¹ Global Brain Health Institute, San Francisco, CA, USA

² Grupo de Neurociencias de Antioquia, Medellin, Colombia

³ www.gna.org.co/, Medellin, Colombia

⁴ Universidad de Antioquia, Medellin, Colombia

⁵ Memory and Aging Center, University of California San Francisco, San Francisco, CA, USA

⁶ Grupo de Neurociencias de Antioquia of Universidad de Antioquia, Medellin, Colombia

⁷ Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellin, Colombia

Correspondence

Claudia Patricia Ramos-Perez, Global Brain Health Institute, San Francisco, CA, USA
Email: claudia.ramos@gbhi.org

Abstract

Background: Substance use is a presumed risk factor for Alzheimer's Disease (AD). So, it would be essential to evaluate it in people who already have a high risk of dementia. Neuroscience Group of Antioquia, GNA, is a research group from Medellin, Colombia, which studies Presenilin 1 (PS1) E280A mutation carriers. These carriers will course four stages of AD: 1) asymptomatic Pre-Mild Cognitive Impairment (Pre-MCI), 2) symptomatic pre-MCI, 3) MCI; and 4) Dementia. Substance consumption could modify age-at-onset of those stages, but this association has not been deeply explored.

Method: We performed a retrospective cohort study with 163 subjects enrolled between January 25, 2019, and April 29, 2020. Of those participants, 69 (42.3%) were non-carriers, and 94 (57.7%) were carriers. A psychiatrist interviewed the subjects through the "CACoS" questionnaire, an instrument specifically designed for this research. The subjects' cognitive information included CERAD test battery, MMSE, CDR, and a subjective memory complaints checklist. We analyzed the relationship between the onset of AD stages and substance consumption through a time-to-event analysis (survival analysis and Cox proportional hazards regression).

Result: For dementia onset, there was an association with less than one time per month of alcohol consumption in the last year (HR 0.42, CI 0.18-0.96). For MCI onset, there was a relationship with less than one time per month of alcohol consumption in the last year (HR 0.39, CI 0.17-0.91), and also with consumption of 5 to 11 drinks per day of consumption in the previous twelve months (HR 0.12, CI 0.01-0.99). For pre-MCI onset, there was a relationship with daily coffee consumption throughout life (HR 2.37, CI 1.07-5.25).

Conclusion: A low frequency of alcohol consumption could be protective against MCI and dementia, but coffee was associated with Pre-MCI acceleration. It would be critical to continue exploring these substances' role as modifiable risk factors soon.